Canada Spends Logo

Explorez notre analyse du budget 2026

Grant: Catalyst Grant: Post Market Drug Safety and Effectiveness

University of British Columbia

$99,785.00

The BeAMS-50plus Study Benefits and Adverse Effects of Beta-interferon for Multiple Sclerosis patients aged 50 plus

EF 2011-12

Résumé
Multiple Sclerosis (MS) is a relatively common disease of the brain and spinal cord, leading to disability, severe fatigue, and coordination problems. Canada has some of the world's highest rates, with three more Canadians diagnosed every day. However, life expectancy is not dramatically affected; over half of Canadians living with MS are over 50 years of age. There is no known cure and available drugs, such as the beta-interferons (IFNB), are only partially effective, require frequent injections and are expensive. Most studies focus on how well IFNBs work in patients under 50, despite the fact that one in six MS patients starting IFNB are over 50. Fundamentally, we do not know about the possible benefits or side effects associated with IFNB use in these older patients. They can also be dealing with health issues such as comorbidities and multiple drug regimens. Given the estimated 40,000 people with MS in Canada aged over 50, and the increasing popularity of the MS drugs, the beneficial effects of these drugs could translate into a substantial improvement in the health of older people with MS. Conversely, if not effective, then many people could be unnecessarily exposed to these drugs. There have been no studies investigating the relationship between age, MS drug treatment and side effects, including depression. In addition, we will examine whether the IFNBs have beneficial or even harmful effects which are more difficult to measure, but could result in overall changes to health service usage such as hospital admissions and physician visits. This research brings together for the first time data collected for over two decades by physicians and pharmacists contributing to multiple large health databases. Our study is a cost-effective way of spending research dollars, costing the equivalent of placing just one person with MS on IFNB treatment for five years. The study will benefit from its independence from the pharmaceutical industry, the manufacturers of IFNB.
Programme
Catalyst Grant: Post Market Drug Safety and Effectiveness
Emplacement
British Columbia, Canada
Type de bénéficiaire
Academia
Type
Grant
Source
CIHR Funding Decisions Database

Tel que publié

Id
243469
Name
Tremlett Helen L
Region
British Columbia
Country
Canada
Orgtype
Institution Paid; Research Institution
Instname2
Population and Public Health
Theme2
Clinical
Prcname2
Catalyst Grant: Post Market Drug Safety and Effectiveness
Projecttitle
The BeAMS-50plus Study Benefits and Adverse Effects of Beta-interferon for Multiple Sclerosis patients aged 50 plus
Programtype2
Operating Grants
Orgnameinp2
University of British Columbia
Cihramount2
$99,785
Cihrequipment2
$0
Programname2
Catalyst Grant: Post Market Drug Safety and Effectiveness
Keyworddelim
Ageing; Data Linkage; Drug Adverse Effects; Drug Effectiveness; Epidemiology; Health Care Utilization; Middle Age; Multiple Sclerosis; Underrepresented Populations
Abstract
Multiple Sclerosis (MS) is a relatively common disease of the brain and spinal cord, leading to disability, severe fatigue, and coordination problems. Canada has some of the world's highest rates, with three more Canadians diagnosed every day. However, life expectancy is not dramatically affected; over half of Canadians living with MS are over 50 years of age. There is no known cure and available drugs, such as the beta-interferons (IFNB), are only partially effective, require frequent injections and are expensive. Most studies focus on how well IFNBs work in patients under 50, despite the fact that one in six MS patients starting IFNB are over 50. Fundamentally, we do not know about the possible benefits or side effects associated with IFNB use in these older patients. They can also be dealing with health issues such as comorbidities and multiple drug regimens. Given the estimated 40,000 people with MS in Canada aged over 50, and the increasing popularity of the MS drugs, the beneficial effects of these drugs could translate into a substantial improvement in the health of older people with MS. Conversely, if not effective, then many people could be unnecessarily exposed to these drugs. There have been no studies investigating the relationship between age, MS drug treatment and side effects, including depression. In addition, we will examine whether the IFNBs have beneficial or even harmful effects which are more difficult to measure, but could result in overall changes to health service usage such as hospital admissions and physician visits. This research brings together for the first time data collected for over two decades by physicians and pharmacists contributing to multiple large health databases. Our study is a cost-effective way of spending research dollars, costing the equivalent of placing just one person with MS on IFNB treatment for five years. The study will benefit from its independence from the pharmaceutical industry, the manufacturers of IFNB.
Competitiondate
201110
Approvedterm2
1 yr 0 mth
Pinamesdelim
Tremlett, Helen L
Approvedterm
1 an 0 mois
Cihrcontribution2
~ $99,785~ $0~
University of British Columbia - $99,785 Grant (2011-… | Canada Spends